Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.55 |
| ▸ | RXRB | P28702 | 3/20 | 0.55 |
| ▸ | RXRG | P48443 | 3/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803357 | 0.88 | SMPD1 (0.54) | RXRARXRBRXRGMRGPRX4NPC1 | |
| SCHEMBL29556736 | 0.86 | MRGPRX4 (0.62) | RXRARXRBRXRGMRGPRX4POLB | |
| SCHEMBL1600077 | 0.86 | MRGPRX4 (0.62) | RXRARXRBRXRGMRGPRX4POLB | |
| Hydrochloric Acid SCHEMBL10857748 | 0.85 | MRGPRX4 (0.61) | RXRARXRBRXRGMRGPRX4POLB | |
| SCHEMBL7863787 | 0.83 | MRGPRX4 (0.56) | RXRARXRBMRGPRX4POLBCASP6 | |
| SCHEMBL3548452 | 0.83 | RXRA (0.75) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL17835565 | 0.82 | SMPD1 (0.61) | RXRARXRBRXRGMRGPRX4POLB | |
| SCHEMBL16372463 | 0.81 | TSHR (0.64) | MRGPRX4RAB9A | |
| SCHEMBL3375128 | 0.81 | CA12 (0.61) | MRGPRX4POLBCASP6RAB9ASMPD1 | |
| SCHEMBL13434463 | 0.81 | SMPD1 (0.60) | RXRARXRBRXRGMRGPRX4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | RXRA 1047/4885RXRB 973/4885RXRG 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.